Fusion Gene Analysis. ncounter Elements. Molecules That Count WHITE PAPER. v1.0 OCTOBER 2014 NanoString Technologies, Inc.

Similar documents
Tech Note. Using the ncounter Analysis System with FFPE Samples for Gene Expression Analysis. ncounter Gene Expression. Molecules That Count

ncounter Vantage 3D RNA:Protein Solid Tumor Assay

ncounter Elements TagSets General Purpose Reagents PACKAGE INSERT Molecules That Count NanoString Technologies, Inc.

Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL

ncounter Analysis System Digital Technology for Pathway-based Translational Research Molecules That Count NanoString Technologies

Best Practices for Clinical Research Biomarker Studies Using the ncounter Platform:

Sample Flexibility for Gene Expression Analysis with the ncounter Analysis System

Archer ALK, RET, ROS1 Fusion Detection v1 Illumina Platform

QIAGEN s NGS Solutions for Biomarkers NGS & Bioinformatics team QIAGEN (Suzhou) Translational Medicine Co.,Ltd

Expression Array System

QPCR ASSAYS FOR MIRNA EXPRESSION PROFILING

Cancer Genetics Solutions

Technical Review. Real time PCR

Lecture #1. Introduction to microarray technology

DNA/RNA MICROARRAYS NOTE: USE THIS KIT WITHIN 6 MONTHS OF RECEIPT.

ncounter mirna Expression Assay User Manual

ncounter Analysis System For Translational Research nanostring.com FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

3.1.4 DNA Microarray Technology

ncounter Low RNA Input Amplification Kit

Performance verification of the automated NuGEN WT-Ovation FFPE RNA Amplification System

Functional DNA Quality Analysis Improves the Accuracy of Next Generation Sequencing from Clinical Specimens

Gene Expression Technology

Roche Molecular Biochemicals Technical Note No. LC 10/2000

State-of-the-art RNA Sequencing for Drug Discovery

resequencing storage SNP ncrna metagenomics private trio de novo exome ncrna RNA DNA bioinformatics RNA-seq comparative genomics

Fluorescent in-situ Hybridization

Methods of Biomaterials Testing Lesson 3-5. Biochemical Methods - Molecular Biology -

LATE-PCR. Linear-After-The-Exponential

SUPPORTING INFORMATION

Data normalization and standardization

Chapter 1. from genomics to proteomics Ⅱ

Quantitative Real Time PCR USING SYBR GREEN

Roche Molecular Biochemicals Technical Note No. LC 12/2000

ncounter PlexSet Reagents

TECHNOLOGIES AVAILABLE FOR LICENSING AT UNIVERSITY OF DELHI

MassARRAY Genetic Analysis System. Genotyping Methylation Analysis Molecular Typing Somatic Mutation Profiling Quantitative Gene Expression (QGE)

Welcome to. Basic Analysis of NanoString Gene Expression Data: QC, Normalization, and Differential Expression Testing

ncounter Vantage 3D RNA:Protein Immune Cell Signaling Panel for Cell Suspensions

Fluorescent In Situ Hybridization (FISH) Assay

DNA. Clinical Trials. Research RNA. Custom. Reports CLIA CAP GCP. Tumor Genomic Profiling Services for Clinical Trials

Figure S1. Unrearranged locus. Rearranged locus. Concordant read pairs. Region1. Region2. Cluster of discordant read pairs, bundle

Expressed genes profiling (Microarrays) Overview Of Gene Expression Control Profiling Of Expressed Genes

AmoyDx TM RET 14 Mutations Detection Kit

RNA-Seq data analysis course September 7-9, 2015

PrimePCR Assay Validation Report

Contents... vii. List of Figures... xii. List of Tables... xiv. Abbreviatons... xv. Summary... xvii. 1. Introduction In vitro evolution...

Single-Cell Whole Transcriptome Profiling With the SOLiD. System

IQFISH on Dako Omnis. Panel for Lung Cancer. Dako FAST RESULTS. ALK, ROS1, RET and MET IQFISH. Dako Omnis. Agilent Pathology Solutions

User Manual. Version 5. Published February Catalog No. K1021 ~

American Society of Cytopathology Core Curriculum in Molecular Biology

CodeLink Human Whole Genome Bioarray

SMARTer Ultra Low RNA Kit for Illumina Sequencing Two powerful technologies combine to enable sequencing with ultra-low levels of RNA

Deoxyribonucleic Acid DNA

Introduction to BioMEMS & Medical Microdevices DNA Microarrays and Lab-on-a-Chip Methods

Designing TaqMan MGB Probe and Primer Sets for Gene Expression Using Primer Express Software Version 2.0

AmoyDx EGFR Three Mutations Detection Kit

PrimePCR Assay Validation Report

Reagents Description Storage

DNA Microarray Technology

PrimePCR Assay Validation Report

The EORTC Molecular Screening programme SPECTA

Wu et al., Determination of genetic identity in therapeutic chimeric states. We used two approaches for identifying potentially suitable deletion loci

7/24/2012. DNA Probes. Hybridization and Probes. CLS 420 Immunology & Molecular Diagnostics. Target Sequences. Target Sequences. Nucleic Acid Probes

IsoFluxTM. System. The next generation of CTC Analysis is here

Welcome to the NGS webinar series

PrimePCR Assay Validation Report

SureSelect XT HS. Target Enrichment

Agilent s Mx3000P and Mx3005P

Simultaneous detection of mirna and mrna on TaqMan Array Cards using the TaqMan Advanced mirna workflow

Solutions will be posted on the web.

A new paradigm in testing for NSCLC-targeted therapies

Real-Time PCR Principles and Applications

qpcr Quantitative PCR or Real-time PCR Gives a measurement of PCR product at end of each cycle real time

American Society of Cytopathology Core Curriculum in Molecular Biology

Basics of RNA-Seq. (With a Focus on Application to Single Cell RNA-Seq) Michael Kelly, PhD Team Lead, NCI Single Cell Analysis Facility

PrimePCR Assay Validation Report

PrimePCR Assay Validation Report

SALSA MLPA probemix P466-A1 CDC73 Lot A

with Cell Surface-Compatible Universal Cell Capture Kit

ChIP-seq and RNA-seq. Farhat Habib

Complementary Technologies for Precision Genetic Analysis

Introducing QIAseq. Accelerate your NGS performance through Sample to Insight solutions. Sample to Insight

EPIGENTEK. Methylamp Whole Cell Bisulfite Modification Kit. Base Catalog # P-1016 PLEASE READ THIS ENTIRE USER GUIDE BEFORE USE

SideStep Lysis and Stabilization Buffer

Amplicon size (bp) E ± SD

MRC-Holland MLPA. Description version 11; 20 November 2015

Automation of Lexogen s QuantSeq 3 mrna-seq Library Prep Kits on the Biomek FX p NGS Workstation

PrimePCR Assay Validation Report

Table of contents. I. Description...2. II. Principle...2. III. Kit Components...3. IV. Storage...3. V. Features...4. VI. Precautions for Operation...

Measuring gene expression

Motivation From Protein to Gene

Oncomine cfdna Assays Part III: Variant Analysis

Gene expression microarrays and assays. Because your results can t wait

About Strand NGS. Strand Genomics, Inc All rights reserved.

The DIG System. Labeling and Detection of Nucleic Acids

CAPTURE-BASED APPROACH FOR COMPREHENSIVE DETECTION OF IMPORTANT ALTERATIONS

Product Description SALSA MLPA Probemix P438-D2 HLA

PrimePCR Assay Validation Report

Selected Techniques Part I

Introduction to RNA-Seq in GeneSpring NGS Software

Transcription:

Fusion Gene Analysis NanoString Technologies, Inc. Fusion Gene Analysis ncounter Elements v1.0 OCTOBER 2014 NanoString Technologies, Inc., Seattle WA 98109 FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. Molecules That Count Gene Expression Single Cell Gene Expression Copy Number Variation

Fusion Gene Analysis Using ncounter Elements Fusion Gene Analysis Using ncounter Elements Introduction ncounter Elements can be utilized to develop highly multiplexed assays for studying fusion genes in oncology and other fields. This white paper describes a comprehensive solution for analysis of gene fusions that is comprised of two broad design methodologies / imbalance designs and universal junction sequence designs (FIGURE 1). Evaluating / imbalance enables detection of fusion events without prior knowledge of the partner gene, while junction designs enable detection of unique junction sequences. Combining these design methods enables the development of robust, highly multiplexed assays for fusion gene analysis. Chromosomal rearrangements can form fusion genes and have an important role in the initial steps and progression of tumorigenesis. Such a gene often has a product with a novel function relative to the two genes that were fused into a single chimeric transcript. In recent years, fusion genes have been found in many hematological and solid tumors, demonstrating that chromosomal aberrations are a common cause of malignancy. An increasing number of fusion genes are being recognized as important diagnostic and prognostic indicators in human cancers, increasing the value of correctly identifying and quantifying the expression of unique fusion events. A / Imbalance Design / Imbalance Design Probes Probes Wild Type Gene Fusion Breakpoint Probes Fusion Gene FIGURE 1: Illustration of the two design methodologies. (A) / imbalance design uses flanking probes to measure expression of exons located and of the breakpoint of a given gene; the exact number of probes can vary by application. A ratio of expression of probes vs. probes that diverges from 1 is indicative that a fusion event has occurred. (B) Junction probes span a unique fusion junction and use toehold exchange technology for greater specificity. B Junction Junction Probe Design Note: Results may vary depending on assay design, sample input, or other factors. Overview of ncounter Elements Elements chemistry uses a common Capture Tag and multiple Reporter Tags supplied by NanoString, which the user customizes through the addition of oligonucleotide probes (Probe A and Probe B for each target) that complement these tags and the targets of interest. Each Probe A recognizes a unique Reporter Tag and its assigned target, while each Probe B recognizes its target and the common Capture Tag. This is distinct from standard ncounter chemistry, in which the Reporter Probe and Capture Probe are manufactured with the target recognition sequences included. 2

NanoString Technologies, Inc. WHITE PAPER / Imbalance Designs Fusion events can be detected with a flanking ncounter Elements probe design that compares the ratio of gene expression upstream and downstream of the fusion junction (FIGURE 1A). Each fusion partner may have promoters with varied strength or activity, and after fusion some exons will be influenced by new promoters (those associated with their fusion partner). The reciprocal fusion gene may even be lost due to an unbalanced translocation event. Therefore, a ratio of / expression for a given gene that diverges from 1 suggests that a fusion event has occurred. This approach can be utilized for discovery of new fusion genes 1 or to develop robust assays for characterization of high-value samples 2,3. Suehara et al. (2012) validated the use of ncounter technology for discovery of novel fusion genes on the basis of / imbalance. They first examined several cell lines as well as samples from patients with lung adenocarcinoma containing known fusions. ncounter results were highly concordant with the results of other established protocols, including fluorescent in situ hybridization (FISH), RT-PCR, and immunohistochemistry. In a separate set of samples from patients who tested negative for known oncogenic drivers, Suehara et al. used the / imbalance assay to identify novel tyrosine kinase fusions. Screening 90 tyrosine kinases and 3 serine/threonine kinases, two 100-base regions were selected for each gene transcript. A probe pair targeted a region upstream of the kinase domain exons, and a probe pair targeted a region within those exons or further. Aberrant / ratios were identified in two cases, involving either RET or ROS1, and once detected these novel fusions could be further characterized. Lira et al. (2013) later developed a similar assay to characterize EML4-ALK fusion variants, which have been identified in approximately 5% of non-small-cell lung carcinomas and are highly responsive to crizotinib (Xalkori, Pfizer). Multiple upstream and downstream probe sets were used to develop a very robust assay that performs well compared to standard clinical assays (FISH and IHC). The resulting approach was later expanded to include simultaneous detection of fusions involving RET or ROS1 3, which may also respond to crizotinib and encompass an additional 2% of non-small cell lung carcinomas. Data provided to NanoString by Kindstar Global* demonstrates the effectiveness of a / imbalance design for detecting fusion events involving the ALK gene without knowledge of the fusion partner. For this assay, 4 probes were placed upstream and 4 probes were placed downstream of the fusion junction. FIGURE 2 shows the counts generated by these probes for a wild type ALK and an ALK fusion sample. In the sample containing an ALK fusion, there is a clear imbalance in the expression levels of the probes compared to the probes. ALK fusion samples exhibited significantly greater expression of the exons only, indicating that a fusion event placed these exons under control of a different, more active promoter. Wild Type ALK Sample ALK Fusion Sample Counts 400 200 / Ratio = 1.000 / Ratio = 0.025 Counts 400 200 Alk 1 Alk 2 Alk 3 Alk 4 Alk 1 Alk 2 Alk 3 Alk 4 Alk 1 Alk 2 Alk 3 Alk 4 Alk 1 Alk 2 Alk 3 Alk 4 Probes Probes Probes Probes FIGURE 2: Differential expression of wild type and fusion ALK exons. Wild type ALK and ALK fusion samples were each assayed using four probes upstream and downstream of the fusion junction. Expression of the ALK exons is significantly altered in the ALK fusion. Note: Results may vary depending on assay design, sample input, or other factors. * Learn more about Wuhan Kindstar Diagnostics Co., Ltd. ( Kindstar Global ) by visiting http://www.kindstarglobal.cn/aboutpro.html. 3

Fusion Gene Analysis Using ncounter Elements Universal Junction Sequence Designs ncounter Elements technology can also be used to characterize specific fusion junctions (FIGURE 1B) by utilizing a new technology, toehold exchange probes, described by Zhang et al. (2012). NanoString can design highly specific probes for virtually any fusion junction sequence as well as other splice variants of interest. Experiments utilizing this universial junction sequence design include an additional oligonucleotide in the hybridization; this adds a single pipetting step to the hybridization protocol for preparing 12 samples. Hundreds of junction probes can be multiplexed together in a single reaction. Toehold exchange designs that span the fusion junction can be incorporated into the existing user-supplied probes used with ncounter Elements reagents, enabling detection and discrimination of unique fusion events. A multiplexed assay containing probes for 7 distinct BCR-ABL fusions was run using total RNA from two cell lines, SUP-B15 and K562, each known to contain a specific fusion gene (FIGURE 3). Human reference RNA was also included in the assay as a negative control. Robust counts were obtained only for the correct fusion in each cell line. No cross-hybridization was detected for any of the incorrect probes, i.e., those that shared one fusion partner but not the other. This indicated that the assay afforded highly specific detection of unique junction sequences. Furthermore, the assay was able to measure the relative expression of each fusion gene in the two cell lines. The ncounter Analysis System does not require amplification, and data exhibit an extremely high signal-to-noise ratio. Samples with as little as 10% of fusioncontaining RNA can be detected. To demonstrate this high sensitivity, 5 ng of total RNA extracted from several fusion-expressing cell lines was mixed with Human Reference RNA in a 1:10 ratio, and 50 ng of the combined RNA sample was run in a multiplexed ncounter Elements fusion assay (FIGURE 4). The correct fusion was clearly detected in each cell line. Fusion probe counts ranged from approximately 50 to 250, well above the calculated background threshold level of 9 counts. Cross hybridization rates of all other fusion probes from the same fusion families were below background (data not shown). BCR-ABL Fusions BCR/ABL Fusions SUP-B15 Cell Line RNA e1a3 e19a2 b3a2 e1e3 e1e2 e13e3 e13e2 0 1000 2000 3000 K562 Cell Line RNA Counts Human Reference FIGURE 3: Multiplexed analysis of BCR/ABL fusions. Robust counts were obtained only for the correct fusion in each cell line, using human reference RNA as a negative control. Fusion Probe Counts Background Threshold Level Fusion Transcript Cell Line 250 200 150 100 50 BCR-ABL (b3a2) BCR-ABL (e1e2) NOTCH1 (ex2-28) K562 (5 ng) SUP-B15 (5 ng) CRL-2331 (5 ng) FIGURE 4: Fusions detected in the presence of 90% normal RNA. Counts for each fusion target were well above the background threshold even when RNA from fusion-containing cell lines was mixed with human reference RNA. 4

NanoString Technologies, Inc. WHITE PAPER Toehold Exchange Technology Traditional probe designs for fusion junctions risk cross-hybridization with sequences that are only partially complementary. In the absence of a perfect complementary target, single-stranded probes can exhibit low-level einteractions with other, highly similar targets. This phenomenon often impacts gene fusion families because a probe for one family member may match either the or exon at the fusion junction of a different family member. To detect unique fusion junctions with ncounter Elements, the design of Probe A one of two user-supplied oligonucleotide probes is modified using toehold exchange technology, and a protector oligonucleotide is added that provides a perfect complement to Probe A and competes with off-target interactions. These modifications to the end of each Probe A enable specific detection of exon-exon junction sequences with very low cross-hybridization (typically less than 0.5%) to transcripts containing either exon alone. toehold region balancer region Protector Oligo rget FIGURE 5: Diagram of toehold exchange probe design. Probe A forms a partially double stranded complex with a protector oligonucleotide. This complex contains a singlestranded toehold region, a double stranded balancer region, and a double-stranded region in the middle complementary to both the protector oligonucleotide and the target. (The Reporter Tag is not shown in this illustration.) Combining the protector oligonucleotide with Probe A forms a partially double-stranded complex, which contains one double-stranded target-non-specific region (the balancer ), one double-stranded target-specific region, and one single-stranded target-specific region (the toehold ; FIGURE 5). Toehold and balancer regions are designed to be similar in length, base composition, and thermodynamic binding strength. As a result, the difference in the hybridization free energy between the protector:probe complex and the target:probe complex approximates zero, and an equlibrium is ultimately reached between hybridization with the protector oligonucleotide or the true target (FIGURE 6A) with an average 50% of probes bound to the target. In the presence of other, non-perfect matches, the difference in the hybridization free energy is much less favorable even if the target is partially complementary (e.g., wildtype transcripts or another fusion variants). The vast majority of probes in such cases will remain bound to the protector oligonucleotide (FIGURE 6B). A Fusion Junction Is a Perfect Match B Target Is Wildtype or a Different Fusion Junction Reporter Tag Reporter Tag Probe A Biotin Protector Probe B Fusion junction Probe A Biotin Protector Probe B Wildtype ΔG 0 kcal/mol Reporter Tag ΔG >> 0 kcal/mol Reporter Tag Protector Protector Biotin Probe A Probe B Biotin Probe A Probe B FIGURE 6: Equilibrium established between the Elements Fusion probes and the hybridization complex. (A) The difference in the hybridization free energy between protector:probe and target:probe is roughly zero, resulting in a large proportion of target:probe complexes. (B) Hybridization between the protector-bound probe and a non-specific sequence (indicated by a red circle) is highly unfavorable even if that sequence is partially complementary. 5

Fusion Gene Analysis Using ncounter Elements In the presence of the intended target, Probe A can undergo strand exchange and hybridize to the biological target instead of the protector olignucleotide. Hybridization of Probe A to the desired target is initiated at the singlestranded toehold region, proceeds through a branch migration process, and is completed via spontaneous dissociation of the balancer region to release the single stranded protector (FIGURE 7). While the toehold region is part of the target-specific portion of Probe A, the balancer region is carefully designed from a database of random unique sequences with no homology to known sequenced species indexed by the External RNA Controls Consortium (ERCC). This design results in highly specific detection of correct targets and makes offtarget hybridization events very energetically unfavorable. A B Target balancer region toehold region Protector Oligo balancer region Conclusion Highly multiplexed assays for detecting gene fusion events can be developed with ncounter Elements. Assays based on this approach are capable of accurately detecting and discriminating fusion events (including unique fusion junctions) in FFPE and fresh frozen patient tissue as well as cell lines. Evaluating / imbalance enables detection of fusions involving a given gene without knowledge of its partner gene(s). Junction probe designs enable the specificity required for detecting unique fusion junctions and utilize toehold exchange technology to overcome the risk of cross-hybridization with similar sequences. Combining both methods in a single assay can provide orthogonal approaches to detecting the known fusion and the ability to detect novel fusion events. References C Target Target toehold region Protector Oligo toehold region Protector Oligo FIGURE 7: Toehold probe hybridization. (A) The target nucleic acid initially hybridizes with the target-specific, single-stranded toehold region. (B) Probe-target hybridization continues through branch migration (indicated by the black arrow) as the protector oligo dissociates. (C) The balancer region is becomes single-stranded after the probe hybridizes with the target. (The Reporter Tag is not shown in this illustration.) balancer region 1. Suehara et al. (2012) Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mrna-based screen for tyrosine kinase fusions. Clin Cancer Res 18(24):6599-6608. 2. Lira et al. (2013) Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn 15(1):51-61. 3. Lira et al. (2014) A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J Mol Diagn 16(2):229-243. 4. Zhang et al. (2012) Optimizing the specificity of nucleic acid hybridization. Nat Chem 4(3):208-214. 6

Fusion Gene Analysis NanoString Technologies, Inc. NanoString Technologies, Inc. 530 Fairview Ave N Suite 2000 Seattle, WA 98109 USA Toll-free: 1 888 358 6266 Fax: 206 378 6288 www.nanostring.com info@nanostring.com LEARN MORE To learn more about ncounter Elements, visit www.nanostring.com/elements or contact your local NanoString Technologies representative. SALES CONTACT United States: us.sales@nanostring.com Europe: europe.sales@nanostring.com Other Regions: info@nanostring.com 2014 NanoString Technologies, Inc. All rights reserved. NanoString, NanoString Technologies, ncounter, Molecules That Count, ndesign, and ncounter Elements are registered trademarks or trademarks of NanoString Technologies, Inc., ( NanoString ) in the United States and/or other countries. All other trademarks and/or service marks not owned by NanoString that appear in this document are the property of their respective owners. The manufacture, use and/or sale of NanoString product(s) may be subject to one or more patents or pending patent applications owned by NanoString or licensed to NanoString from Life Technologies Corporation and other third parties. FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. OCTOBER 2014 v.20141001

www.nanostring.com info@nanostring.com 1 888 358 6266